Skip to content

Clinical observation of Itraconazole using in infant hemangioma

Clinical observation of Itraconazole using in infant hemangioma

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPS-14005255
Enrollment
Unknown
Registered
2014-08-03
Start date
2015-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infant hemangioma

Interventions

1:Itraconazole

Sponsors

Sichuan University
Lead Sponsor

Eligibility

Age
No minimum to 2 Years

Inclusion criteria

Inclusion criteria: Subjects must satisfy the following criteria to be enrolled in the study: Male or female, age of 1 month to 24 months; being diagnosed of hemagioma; nothing wrong with blood routine examination, electrocardiogram, stool and urine routine tests, hepatorenal and kidney function,cardiac function, immunologic function, gastrointestinal function; not allagic to Itroconazole; have not taken any other drugs for hemagioma in 4 weeks, completely.

Exclusion criteria

Exclusion criteria: Potential subjects who meet any of the following criteria will be excluded from participating in the study: Age less than 1 month or age older than 24 months; not being diagnosed as hemagioma; anything wrong with blood routine examination, electrocardiogram, stool and urine routine tests, hepatorenal and kidney function, cardiac function, immunologic function, gastrointestinal function; being allergic to Itroconazole; have taken other drugs for hemagioma in 4 weeks; bad treatment compliance.

Design outcomes

Primary

MeasureTime frame
diameter of hemagionma;

Countries

China

Contacts

Public ContactRanYuping
ranyuping@vip.sina.com+86 028-85422792

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026